Illumina, Inc. (NASDAQ:ILMN) today announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.
“We’ve significantly expanded our fleet of Genome Analyzers to ramp up our sequencing capabilities in whole genome, whole exome, and whole transcriptome analysis,” said Robert Nicol, director of Sequencing Operations at the Broad Institute. “We are happy with the technology’s accuracy, ease of use and scalability, as well as continued system improvements that have recently enabled us to generate multiple runs with more than 50 gigabases of high quality sequence data.”
“This latest purchase by the Broad Institute is another strong vote of confidence in Illumina’s Genome Analyzer technology and its capacity to evolve to meet the future needs of one of the world’s leading genome centers,” said Matt Posard, vice president of Worldwide Sales at Illumina. “We continue to focus our innovation on simplifying workflow, enhancing scalability and increasing high-quality runs, as the scope of genetic research expands dramatically.”